GLP-1 Medicines, Diabetes & Brain Metastases: Research

From Blood Sugar to Brain Metastases: An Unexpected Plot Twist

A 2026 retrospective cohort study found that GLP-1 receptor agonist use was associated with lower all-cause mortality in people who had type 2 diabetes, cancer and brain metastases. The study included semaglutide, dulaglutide, liraglutide and tirzepatide. After propensity-score matching, GLP-1 RA users had a 37% lower relative hazard of death than matched nonusers. However, this was an observational study and does not prove that GLP-1 medicines caused longer survival or treated brain metastases.

GLP-1 medicines have transformed the treatment of type 2 diabetes and obesity. Their effects on blood sugar, body weight and cardiovascular health are now well established. But researchers are beginning to ask a much bigger question: could these medicines also influence what happens when cancer reaches the brain?

Brain metastases occur when cancer cells from another part of the body travel to the brain and establish new tumours. They can cause neurological symptoms and are associated with substantial morbidity and mortality. When type 2 diabetes is present as well, metabolic and inflammatory factors can add another layer of complexity.  That makes a newly published 2026 study particularly interesting. Researchers found an association between GLP-1 receptor agonist use and longer survival in people with cancer, brain metastases and type 2 diabetes. The result is intriguing, but it is not yet evidence that GLP-1 medicines are cancer treatments.

What Are GLP-1 Medicines?

GLP-1 receptor agonists, or GLP-1 RAs, mimic the action of glucagon-like peptide-1, a hormone involved in glucose regulation and appetite. They can increase glucose-dependent insulin secretion, reduce glucagon release, slow gastric emptying and influence appetite.

The medicines investigated in the brain-metastasis study included semaglutide, dulaglutide and liraglutide. Tirzepatide was also included, although technically it is a dual GIP/GLP-1 receptor agonist, because it activates both GIP and GLP-1 pathways rather than GLP-1 alone.  Their established clinical roles are metabolic. Any possible effects on cancer or the brain remain a research question.

Why Might GLP-1 Signalling Matter to the Brain?

Scientists are interested in GLP-1 signalling because it does more than influence glucose. Experimental research has explored its relationships with inflammation, oxidative stress, mitochondrial function and blood-brain-barrier integrity. GLP-1 receptor activation has also demonstrated anti-inflammatory and potentially neuroprotective effects in experimental models.

These observations provide biological reasons to investigate GLP-1 medicines in neurological and cancer settings. But a plausible mechanism is not proof of a clinical benefit. Laboratory findings cannot establish that a person with brain metastases will live longer because they take a GLP-1 medicine.

The Key Study: Diabetes, Cancer and Brain Metastases

The most directly relevant evidence comes from Chi and colleagues, published in JAMA Network Open in March 2026. This retrospective cohort study used the TriNetX Global Network, a federated database involving 151 healthcare organizations. Researchers identified adults with cancer, brain metastases and type 2 diabetes between January 2018 and January 2024. They compared people who had received GLP-1 RAs with people who had not. The primary outcome was all-cause mortality over up to three years from the study index date. Researchers also examined different cancer types, individual GLP-1-related drugs and comparisons with other antidiabetic treatments.

Among 19,234 eligible patients, 866 were GLP-1 RA users and 11,103 were nonusers. After propensity-score matching, 850 GLP-1 RA users were compared with 850 matched nonusers. Propensity matching attempts to make the groups more comparable by balancing measured characteristics that could influence the outcome.

What Did the Researchers Find?

GLP-1 RA use was associated with significantly lower all-cause mortality. The hazard ratio was 0.63, with a 95% confidence interval of 0.54 to 0.72. In relative terms, that represents about a 37% lower hazard of death during the study period among GLP-1 RA users compared with matched nonusers.

The association was reported as generally consistent across major cancer types and GLP-1 RA types, except liraglutide, and was also observed when researchers compared GLP-1 RA users with people receiving other antidiabetic therapies. Falsification outcomes like seizures and pneumonia; were comparable between groups, which provided some additional reassurance that the result was not simply explained by an obvious imbalance.  But this was still an observational association. The study cannot tell us whether GLP-1 medicines themselves produced the survival difference.

Four GLP-1 Drugs, Four Different Groups: So What Did Researchers Find?

One particularly useful feature of the study is that it identified the individual drugs rather than treating every exposure as an unnamed GLP-1 medicine.

• Semaglutide: 369 patients
• Dulaglutide: 379 patients
• Liraglutide: 147 patients
• Tirzepatide: 95 patients

Semaglutide and dulaglutide therefore represented the largest groups. Tirzepatide had the smallest group, making drug-specific conclusions particularly uncertain. The overall association was described as consistent across GLP-1 RA types except liraglutide. This does not mean liraglutide was shown to increase mortality; rather, the same statistically consistent association was not observed for that drug.  Most importantly, the study does not prove that semaglutide, dulaglutide, liraglutide or tirzepatide independently improves survival in brain metastases. The individual drug groups were not large enough to support that conclusion.

What Cancer Types Were Involved?

The study included people whose cancers had spread to the brain from different primary sites. Researchers examined the results across major cancer types and reported that the overall mortality association was generally consistent across those groups.  This is useful because brain metastases are not a single disease. Lung cancer, breast cancer, melanoma and other cancers can behave differently, respond to different treatments and have different patterns of spread. A finding that appears across several cancer categories is therefore more interesting than one confined to a single tumour type. Still, subgroup consistency does not prove that GLP-1 medicines directly affect each cancer in the same way.

GLP-1 RA Users Versus Nonusers: Why the Comparison Matters

Simply comparing people who take GLP-1 medicines with everyone who does not take them can be misleading. People prescribed GLP-1 drugs may differ in many ways from nonusers. They may have different healthcare access, weight, diabetes severity, cardiovascular risk, treatment patterns or socioeconomic circumstances. That is why the investigators used propensity-score matching. They also compared GLP-1 RA users with people receiving other antidiabetic therapies. These approaches strengthen the analysis, but they cannot eliminate every possible source of confounding.

For example, the researchers could not fully assess individual medication doses, treatment duration or the details of systemic cancer therapy and radiation treatment.

Does This Mean GLP-1 Medicines Treat Brain Metastases?

No. This is the most important distinction in the entire story. The study measured all-cause mortality. It did not establish that GLP-1 medicines shrank brain tumours, prevented new metastases, delayed tumour progression or improved cancer-specific survival. It also did not demonstrate that the medicines crossed into the brain and directly attacked metastatic cancer cells. The observed survival difference could involve multiple pathways or factors that were not measured at all.

Is the Brain-Metastasis Finding an Isolated Observation?

Not entirely. Other recent research has also begun examining GLP-1 medicines in people with cancer, although the evidence is still largely observational.

A 2026 JAMA Network Open study of women with breast cancer used TriNetX data and examined GLP-1 RA use in relation to mortality and recurrence-free survival. The analysis included more than 841,000 women with breast cancer overall, with separate propensity-matched comparisons involving obesity and type 2 diabetes. The results suggested lower mortality and recurrence in some GLP-1 RA comparisons, particularly against insulin or metformin, while the comparison with SGLT2 inhibitors was less consistent.

Another 2026 ASCO meeting abstract examined stage I–III colorectal cancer using TriNetX data. Among 20,383 identified patients, 839 per group remained after propensity matching. GLP-1 RA use was associated with better recurrence-free and overall survival than nonuse. However, this was a meeting abstract rather than a full peer-reviewed article, so the findings should be treated as preliminary.  These studies make the brain-metastasis finding more interesting, but they do not turn observational associations into proof.

What Do Randomized Trials Say About Cancer Risk?

This is where the evidence becomes particularly important. A meta-analysis of 50 randomized controlled trials, including more than 100,000 participants across GLP-1 RA and comparator groups, found no significant difference in overall cancer risk between GLP-1 RAs and comparators. The analysis included studies involving liraglutide, semaglutide, dulaglutide and other GLP-1 medicines.

The researchers did identify signals involving thyroid and colorectal cancer, but these findings require cautious interpretation and further investigation. Importantly, randomized trials have not demonstrated a broad cancer-prevention or cancer-treatment effect from GLP-1 RAs. This distinction is essential: a medicine can be associated with better survival in an observational cancer cohort without having been proven to directly treat cancer.

What About the Individual Medicines?

The existing evidence should not be interpreted as four separate demonstrations of anticancer efficacy.

Semaglutide has substantial clinical-trial exposure because of its use in diabetes and obesity. The brain-metastasis cohort included 369 users, and semaglutide is also represented in broader randomized safety analyses. These data are useful for assessing safety and associations but do not establish an anticancer indication.

Dulaglutide had the largest subgroup in the brain-metastasis study, with 379 users. It has also been evaluated extensively in diabetes trials, including cancer-safety analyses. Again, those trials do not establish that dulaglutide treats metastatic cancer.

Liraglutide had 147 users in the brain-metastasis cohort. Unlike the overall GLP-1 RA result, the mortality association was not consistently observed for liraglutide. This is an important reason not to lump every drug together and assume identical effects.

Tirzepatide had 95 users. Because tirzepatide targets both GIP and GLP-1 receptors and the subgroup was relatively small, the brain-metastasis study cannot establish a specific survival benefit for tirzepatide. Its inclusion makes it relevant to the emerging research landscape but not a proven cancer therapy.

Recent Research Highlights

The current evidence can be summarized as follows:

• 2026 brain-metastasis study: 19,234 people with cancer, brain metastases and type 2 diabetes were identified; 866 were GLP-1 RA users. After matching, GLP-1 RA use was associated with lower all-cause mortality, HR 0.63.
• Individual drugs: Semaglutide, 369 users; dulaglutide, 379; liraglutide, 147; tirzepatide, 95. The overall association was generally consistent except for liraglutide.
• Breast cancer, 2026: A large retrospective TriNetX study found favorable associations between GLP-1 RA use and survival/recurrence in certain comparisons, but results differed according to the comparator group.
• Colorectal cancer, 2026: A preliminary ASCO analysis reported better recurrence-free and overall survival among GLP-1 RA users than nonusers, but prospective trials remain necessary.
• Randomized evidence: A 50-trial meta-analysis found no significant overall cancer-risk difference between GLP-1 RAs and comparators.
• Large real-world cancer-risk study: A 2026 TriNetX analysis matched 144,410 GLP-1 RA users with 144,410 nonusers to examine mortality and incident cancers, highlighting how actively this question is being investigated.

Recent Clinical Studies & Surveys

There are no established randomized clinical trials showing that semaglutide, dulaglutide, liraglutide or tirzepatide improves survival specifically in people with brain metastases. The strongest direct evidence remains the 2026 retrospective TriNetX cohort. This matters because observational databases are excellent for detecting signals that might otherwise take years to notice, but they cannot fully reproduce the control provided by randomization. The brain-metastasis investigators specifically noted limitations involving unmeasured variables, cancer treatment details, dose-response information and generalizability.  Consequently, the current evidence supports further investigation rather than a change in cancer treatment practice.

Why Could Metabolic Health Matter?

One possibility is that the apparent survival association has little to do with a direct anticancer action. Better glucose regulation, weight management and cardiovascular health could influence overall resilience in people already dealing with serious cancer.

Another possibility is that GLP-1 signalling itself affects pathways involved in inflammation, oxidative stress or the blood-brain barrier. These mechanisms are biologically plausible and have been investigated experimentally, but they remain hypotheses when it comes to explaining survival in patients with brain metastases.  There may also be a combination of effects or entirely different explanations. That uncertainty is precisely why prospective research matters.

What Does the Evidence Actually Demonstrate?

The strongest conclusion today is surprisingly modest:
GLP-1 RA use is associated with better survival in one large observational population of people with type 2 diabetes, cancer and brain metastases.

The study does not demonstrate that GLP-1 RAs caused the survival advantage.
It does not demonstrate that they kill cancer cells.
It does not demonstrate that they shrink brain metastases.
And it does not justify taking a GLP-1 medicine specifically because of cancer.
What it does provide is a compelling research signal that deserves to be tested in more rigorous prospective studies.

Key Takeaways

• A 2026 study found an association between GLP-1 RA use and lower all-cause mortality in people with type 2 diabetes, cancer and brain metastases.
• The study included semaglutide, dulaglutide, liraglutide and tirzepatide.
• Semaglutide and dulaglutide had the largest individual drug groups.
• The overall mortality association was not consistently observed for liraglutide.
• Tirzepatide was included but had only 95 users in the study.
• GLP-1 RA users were compared with matched nonusers and other antidiabetic-treatment groups.
• The finding was observed across major cancer subgroups.
• The study was retrospective and observational, so it cannot prove causation.
• Randomized-trial evidence has not established GLP-1 medicines as cancer treatments.
• There is currently no evidence that these medicines should be prescribed specifically to treat brain metastases.
• The findings justify further research, not a new cancer indication.

FAQ (Frequently Asked Questions)

1. Could GLP-1 medicines improve survival in people with brain metastases?
   A 2026 observational study suggests they might be associated with longer survival, but it does not prove that the medicines caused the benefit.

2. Was semaglutide included in the study?
   Yes. There were 369 semaglutide users in the eligible GLP-1 RA group.

3. Was dulaglutide included?
   Yes. Dulaglutide accounted for 379 users, making it the largest individual drug subgroup.

4. What did the study find about liraglutide?
   The overall GLP-1 RA association was not consistently observed for liraglutide. This does not mean liraglutide was proven harmful; the result simply did not show the same statistical pattern.

5. Was tirzepatide included?
   Yes. Ninety-five patients were using tirzepatide. Because it is a dual GIP/GLP-1 agonist and the subgroup was small, the study cannot establish a specific survival benefit for it.

6. Did GLP-1 medicines shrink brain metastases?
   No. The study measured all-cause mortality and did not demonstrate tumour shrinkage or delayed progression.

7. Were GLP-1 users compared only with people taking no diabetes medication?
   No. Researchers examined GLP-1 RA users versus nonusers and also conducted comparisons involving other antidiabetic therapies.

8. Could better diabetes control explain the survival difference?
   It could contribute. The study cannot determine whether the association resulted from glucose control, weight, cardiovascular effects, GLP-1 biology or other differences between treatment groups.

9. Are GLP-1 medicines cancer treatments?
   No. They are not currently established treatments for cancer or brain metastases.

10. Does randomized research show that GLP-1 medicines prevent cancer?
    No broad cancer-prevention effect has been established. A 50-trial randomized meta-analysis found no significant difference in overall cancer risk between GLP-1 RAs and comparators.

11. Why is more research needed?
    Observational studies can identify important associations but cannot completely eliminate confounding. Prospective studies are needed to determine whether GLP-1 medicines themselves influence cancer outcomes.

12. Should someone with cancer start a GLP-1 medicine because of this research?
    No. Decisions about GLP-1 treatment should be based on established indications and an individual’s medical circumstances, with guidance from the treating healthcare team.

DISCLAIMER: The content of this article is intended solely for general informational purposes and is not a substitute for professional medical consultation, diagnosis, or treatment. Always seek the advice of your doctor or another qualified healthcare professional regarding any medical concerns.